 |  |  |
|---|
Excellence in Trans-Atlantic Business Development
Kineto Lab Ltd., Budapest, Hungary
Kineto Lab’s mission is to provide high quality, scientifically based drug screening assays and testing technologies which enhance quality of drug discovery screening.
Kineto Lab Ltd. has extensive expertise in high quality screening assays based on several successful projects completed for pharmaceutical, biotechnology, and academic institutions during the past years.
The company is committed to service excellence, always seeking to exceed the expectations of their partners.
Flow2US, Inc. is exclusive agent and distributor of Kineto Lab Ltd. in the United States.
​
Short description
​
Kineto Lab Ltd. is specialized in developing and using preclinical models for testing various anticancer strategies and treatments.
Kineto Lab Ltd. has substantial experience in using in vivo animal models, such as xeno- and allografts from cell lines and patient derived xenografts, for drug development and screening.
Kineto Lab Ltd. is fully licensed to conduct animal research all the official and ethical licenses for animal research.
​
Kineto Lab Ltd. is a privately owned Hungarian biotech research company founded in 2007 for testing and developing new antitumoral compounds.
The company has extensive expertise in screening assays based on several successful projects completed for pharmaceutical, biotechnology, and academic institutions during the past years.
Kineto Lab’s expert team and partner laboratories manage the whole process of drug development from target specification and molecule design to in vivo animal models through HT in vitro screenings.
​
Kineto Lab’s mission is to provide high quality, scientifically based drug screening assays and testing technologies which enhance quality of drug discovery screening.
The company is committed to innovation and excellence, always seeking to exceed the expectations of partners.
Products, Services, Partnering
Flow2US, Inc. is the exclusive agent and distributor of Kineto Lab Ltd’s products and services in the USA, and in this capacity we seek the attention and interest of oncology focused R&D establishments who are looking to outsource, fully or partially, phases of their pre-clinical drug discovery and development projects to Kineto Lab’s expert team.
Flow2US provides tailored solutions to match your requirements with Kineto Lab’s scientific capacities and extensive experience.
​
We introduce Kineto Lab’s products and technologies to potential and interested partners, and help establish cooperation that match our clients’ requirements and expectations, projects and budgets.
We follow through each project by advising and facilitating the most effective and tailored solutions for all participating partners.
Besides facilitating project based cooperation, Flow2US imports and distributes Kineto Lab’s products in the US market.
The Anti-human CD34 antibody and Anti-human VEGFR2 antibody have been developed by Kineto Lab to.
​
We take care of all importing complexities and manage each order with care thru our business office in Minnesota including all aspects of logistics, such as customs documentation, licenses, permits, certificates, duties, insurance by our experienced brokers, to ensure smooth clearance and compliance with regulatory agencies, if applicable.
​
Are you interested to know more about Kineto Lab’s products and services? Contact us.
Products
Anti-human CD34 antibody
Mouse IgG monoclonal antibody that reacts with human CD34
Anti-human VEGFR2 antibody
Mouse IgG monoclonal antibody that specifically binds to the vascular endothelial growth factor receptor (VEGF-R2)
Services
Kineto Lab Ltd. is an acknowledged expert in development of tailored, predictive screening procedures employing primary patient tumors, xenograft assays and cell based preclinical screening procedures for anticancer agents.
​
For details, visit the following chapters or contact our Minneapolis office:
​
Drug Discovery and Screening
In vivo tumor models
Metastasis models
In-vivo models: Xenografts developed by injection or orthotopic transplantation of various tumor cells and tissues into various target organs in mice.
In-vitro models using tumor cell lines.
Tissue invasion models: 2D and 3D models, intra- and extravasation.
Tumor cell motility assays
Assessment of anti-angiogenic potential
Assessment of anti-metastatic potential
Cell proliferation assays
Apoptosis assays
Partnering
Kineto Lab Inc. is a respected partner for pharmaceutical projects in the fields of preclinical screening and product development of various anticancer agents.
Kineto Lab’s in-house specialist team combined with a network of partners enable the participation in complex R&D projects designed for testing and developing new antitumoral compounds.
​
Cooperation and participation in complex drug development projects
​
Development and testing new screening methods
​
Scientific advisory and counseling on related projects
​
In addition to cooperation on a fee for services basis, we are open to discuss alternative models, such as the risk sharing model of working together.
All products distributed by Flow2Us, Inc. can be ordered on line from our Webstore.
US partners
We are seeking US partners in the following sectors:
In collaboration with Kineto Lab Ltd., we are building partnership with oncology focused R&D establishments whose R&D investment models have solid outsourcing plans.
We are seeking for US partners outsourcing fully or partially phases of their drug discovery and development projects.
​
Potential partners are:
​
-
Pharma industry
-
R&D Biotech startups and early-stage companies
-
Scientific and Academic Institutions working on proof of concept
-
Drug discovery and development R&D establishments
Potential users of Kineto Lab’s Anti-human CD34 antibody and Anti-human VEGFR2 antibody product lines:
​
-
Laboratory diagnostics firms
-
Research institutions and laboratories
​
Organization
Kineto Lab Ltd. is a privately owned Hungarian biotech research company founded by two biologists and one chemist in 2007 for testing and developing new antitumoral compounds.
Kineto Lab currently employs seven R&D professionals. Kineto Lab is fully equipped with instruments for in vitro cell-based analysis and for molecular techniques.
Kineto Lab develops different methods for testing the possible effect of new agents on tumor cell migration, adhesion, matrix interaction, proliferation and programmed cell death (apoptosis).
Kineto Lab has special expertise for testing these agents in different in vivo alli/iso- and xenograft models (i.e. subcutaneous tumor growth, orthotopic transplantation, metastasis models).
​
These techniques can be useful for detecting the possible effect of newly synthesized agents on tumor progression in preclinical investigation phase.
Projects & Activity
Kineto Lab Ltd. develops unique methods to be used along the preclinical drug discovery pipeline to identify and validate new drug targets and to predict in vivo toxicity of anticancer drugs.
The company’s experience in various research grant projects, such as Horizon 2020, the ever biggest research and innovation program of the European Community gives solid scientific basis to offer efficient service in research, development and screening of drug candidates.
​​
-
Peptide-Drug Conjugates for Targeted Delivery in Tumor Therapy
​​
-
Development of detection method for circulating endothelial progenitor cells (EPCs)
​​
Kineto Lab is member of the ”MAGICBULLET” international research consortium built for studying the application of drug conjugates in selective tumor therapy.
​​
This angiogenesis related project has been successfully completed laying down the principles of developing a detection method for enumeration circulating endothelial progenitor cells.
Angiogenesis and vasculogenesis, development of blood vessels are essential steps in the growth of a tumor.
​​
Proposed Ways of Cooperation, Suggested Business Model
Flow2US, Inc. helps Kineto Lab’s team to define their business objectives on the US market, find their US partners or ‘study sponsors’, i.e. the pharmaceutical, biotechnology, and academic institutions partially outsourcing their drug discovery and development projects.
We then create the road map to get the two partners to a mutually beneficial cooperation devising a strategy for the most effective partnering.
Flow2US, Inc. wants to be an interface between Kineto Lab. Ltd. and their US clients.
​
When working on a project for the first time a three-stage process is used before the research service contract is made:
​
Preparation:
The first step is to understand the the objective of the study. The research and scientific team of Kineto Lab are available to answer the questions of the study sponsor before or after the study started.
​
Study Proposal:
In the Study Proposal session, Kineto Lab’s research team provides a research plan and a structured protocol of the study, including the ‘research timetable’ highlighting the expected milestones of the work.
The proposal shall address any confidentiality and intellectual property issues.
​
Any study undertaken by Kineto Lab can be customized. The company works exclusively for the study sponsor (contractual partner).
The results of the study performed by Kineto Lab and the intellectual property generated by the study belong to the sponsor of the study.
​
Statement of Work:
The final version of the Study Proposal accepted by the study sponsor is finalized in a contract that prescribes the terms and conditions to be applied to the study.
The study report should eventually support the investigational new drug (IND) application to be submitted by the drug developers before beginning clinical research.
​
Kineto Lab Ltd. and Flow2US, Inc. have signed an exclusive agency and distribution contract.
The contract is a framework agreement between the two businesses establishing the general terms governing the ’Statement of Work’ contracts which prescribe the terms and conditions to be applied directly to the project agreed by Kineto Lab Ltd., the US partner and Flow2US, Inc.
Uniqueness of KinetoLab’s Products, Services and Technologies
Screening and Testing Portfolio
​
The standard screening and testing portfolio of Kineto Lab Ltd. is shown on the Services pages.
​
In addition, the partners, sponsors can expect:
​
-
Access to up to date facilities of oncology, pathology and laboratory services
-
Experienced clinical and oncological pathology services
-
Strictly monitored turnaround times
-
Advanced IT services, security and electronic data transfer
-
Each project is managed and supported by a dedicated project manager
Development of specialized testing projects
​
Kineto Lab combines testing expertise from Hungary’s largest oncology diagnostic laboratory with strictly validated testing methods and standardized laboratory procedures to deliver the most accurate and trusted screening results.
This allows Kineto Lab’s team to further develop specialized testing for the pharma companies and for the bioresearch community.
R&D aiming Personalized Medicine
​
The leaders and the researchers of the company have recognized that personalized medicine is the ultimate objective in the field of cancer treatment.
Although still in R&D phase, Kineto Lab’s research projects are directed towards novel testing technologies that can be eventually steps towards making personalized cancer medicine.
​
Why Cooperate with KinetoLab
Extensive Experience
​
-
Since 2007, Kineto Lab has been the leading developer and provider of cutting-edge technologies in Hungary with an exclusive focus on the study of preclinical models for testing various anticancer strategies and treatments;
-
The key scientists of the company have more than 20 years of experience in oncology R&D;
-
The company’s screening and research technologies have been widely used and tested by universities, research institutions, leading pharmaceuticals, and hightech biotechnology companies.
Comprehensive Offering
​
-
Kineto Lab’s service packages can be customized to the research needs of the customers. Complex screening or testing projects shall be negotiated and they can be executed under a master service agreement. All services are operated under strict confidentiality terms;
-
Extensive cooperation with the leading experts, specialists, reseach scientists and skilled contract partners;
Speed and Quality
​
-
Excellent responsiveness: Fast response to you inquiries, fast and efficient communication;
-
Realistic, short timeframe, strict deadlines;
-
Straightforward sample submission to Minneapolis (organized and processed by Flow2US, Inc.);
-
Kineto Lab delivers high quality results and data reports.
Certification
​
-
Kineto Lab holds all required regulatory and legal certificates and permits to perform in vivo animal tests;
-
Unique, long term agreements with owners of proprietary materials, cell lines, animal strains;
-
Competitive pricing
​
Competitive Advantages
KinetoLab’s Market Position
In Europe:
​
Kineto Lab Ltd. is a Hungarian biotech research company founded in 2007 for testing and developing new antitumoral compounds.
The company has extensive expertise in screening assays based on several successful projects completed for pharmaceutical, biotechnology, and academic institutions during the past years.
In the USA:
​
Kineto Lab Ltd. and Flow2US, Inc. have signed an exclusive agency and distribution contract. The contract is a framework agreement between the two businesses establishing the general terms governing the ’Statement of Work’ contracts which prescribe the terms and conditions to be applied directly to the project agreed by Kineto Lab Ltd., the US partner and Flow2US, Inc.
Flow2US, Inc. helps Kineto Lab’s team to define their business objectives on the US market, find their US partners or ‘study sponsors’, i.e. the pharmaceutical, biotechnology, and academic institutions partially outsourcing their drug discovery and development projects.
Besides facilitating project based cooperation, Flow2US imports and distributes Kineto Lab’s products in the US market. The Anti-human CD34 antibody and Anti-human VEGFR2 antibody have been developed by Kineto Lab to.
We take care of all importing complexities and manage each order with care thru our business office in Minnesota including all aspects of logistics, such as customs documentation, licenses, permits, certificates, duties, insurance by our experienced brokers, to ensure smooth clearance and compliance with regulatory agencies, if applicable.
​
Are you interested to know more about Kineto Lab’s products and services?
Please contact Flow2US, Inc. the exclusive agent of Kineto Lab in the United States and Canada.
​
IP, Property Rights
Under Construction
Management & Staff
Kineto Lab’s team is committed to service excellence and is focused on helping partners and sponsors get their drug candidates to the clinical testing faster.
The research groups are led by a management team that has extensive depth and expertise in drug development and testing.
Chief Executive Officer
​
Attila Kigyós MSc. is the founder and the Chief Executive Officer of Kineto Lab Research and Development Ltd. In addition to acting as the managing director of the corporation, Attila is a seasoned professional with more than 2 decades of experience in the field of IT, biotechnology and drug discovery screening.
​
Attila was selected as Chief Executive Officer based on his track record of leading Hungarian Biotech companies as executive manager, as well as strong executive and personal qualities.
R&D Director, Vice President
​
Dr. Jozsef Tovari has a strong scientific experience in the field of translational applied research and development in oncology.
He has the essential grant management experiences required by the present project.
He is co-author of 41 scientific publications; his cumulative impact factor is 151. He has 320 independent citations.
​
As Director of Research and Development for Kineto Lab, Jozsef Tovari plays a cruical role in the design and management of the ongoing drug screening tests and services for companies at KinetoLab.
​
Working on a collaborative basis with leading researchers in fields such as Oncology, Respiratory Medicine, Aging, Autism and Neuroscience and most recently in Athletic Performance, he ensures Immunotec's continued leadership position within the nutrition industry.